0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Prophylactic Human Vaccine Market Insights and Forecast to 2028
Published Date: January 2022
|
Report Code: QYRE-Auto-9Q602
Home | Market Reports | Health | Health Conditions | Infectious Diseases
Global Prophylactic Human Vaccine Market Insights and Forecast to 2028

Global Prophylactic Human Vaccine Market Insights and Forecast to 2028

Code: QYRE-Auto-9Q602
Report
January 2022
92 Pages
QYResearch
Region: Global, Japan, Europe, India, Southeast Asia, North America,
Description
Table of Content
Tables & Figures
Vaccination in the body of a healthy person causes the person to produce antibodies and obtain specific immunity in the absence of disease. For example, BCG vaccination, smallpox vaccination and so on.
Market Analysis and Insights: Global Prophylactic Human Vaccine Market

Due to the COVID-19 pandemic, the global Prophylactic Human Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.

Fully considering the economic change by this health crisis, Inactivated Vaccine accounting for % of the Prophylactic Human Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Hospital segment is altered to an % CAGR throughout this forecast period.
China Prophylactic Human Vaccine market size is valued at US$ million in 2021, while the US and Europe Prophylactic Human Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Prophylactic Human Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

The global key manufacturers of Prophylactic Human Vaccine include GSK, Biovac, McKesson Medical, Merck, Merial, Zoetis and Sanofi, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Prophylactic Human Vaccine Scope and Segment
Prophylactic Human Vaccine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Prophylactic Human Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Inactivated Vaccine
Attenuated Vaccine
Others

Segment by Application

Hospital
Scientific Research
Others

BY COMPANY

GSK
Biovac
McKesson Medical
Merck
Merial
Zoetis
Sanofi

BY REGION

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
1 Study Coverage
1.1 Prophylactic Human Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Prophylactic Human Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Inactivated Vaccine
1.2.3 Attenuated Vaccine
1.2.4 Others
1.3 Market by Application
1.3.1 Global Prophylactic Human Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Scientific Research
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Prophylactic Human Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Prophylactic Human Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Prophylactic Human Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Prophylactic Human Vaccine Sales by Region
2.4.1 Global Prophylactic Human Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Prophylactic Human Vaccine by Region (2023-2028)
2.5 Global Prophylactic Human Vaccine Revenue by Region
2.5.1 Global Prophylactic Human Vaccine Revenue by Region (2017-2022)
2.5.2 Global Prophylactic Human Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Prophylactic Human Vaccine Sales by Manufacturers
3.1.1 Global Top Prophylactic Human Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Prophylactic Human Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Prophylactic Human Vaccine in 2021
3.2 Global Prophylactic Human Vaccine Revenue by Manufacturers
3.2.1 Global Prophylactic Human Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Prophylactic Human Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Prophylactic Human Vaccine Revenue in 2021
3.3 Global Prophylactic Human Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Prophylactic Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Prophylactic Human Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Prophylactic Human Vaccine Sales by Type
4.1.1 Global Prophylactic Human Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Prophylactic Human Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Prophylactic Human Vaccine Revenue by Type
4.2.1 Global Prophylactic Human Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Prophylactic Human Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Prophylactic Human Vaccine Price by Type
4.3.1 Global Prophylactic Human Vaccine Price by Type (2017-2022)
4.3.2 Global Prophylactic Human Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Prophylactic Human Vaccine Sales by Application
5.1.1 Global Prophylactic Human Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Prophylactic Human Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Prophylactic Human Vaccine Revenue by Application
5.2.1 Global Prophylactic Human Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Prophylactic Human Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Prophylactic Human Vaccine Price by Application
5.3.1 Global Prophylactic Human Vaccine Price by Application (2017-2022)
5.3.2 Global Prophylactic Human Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Prophylactic Human Vaccine Market Size by Type
6.1.1 North America Prophylactic Human Vaccine Sales by Type (2017-2028)
6.1.2 North America Prophylactic Human Vaccine Revenue by Type (2017-2028)
6.2 North America Prophylactic Human Vaccine Market Size by Application
6.2.1 North America Prophylactic Human Vaccine Sales by Application (2017-2028)
6.2.2 North America Prophylactic Human Vaccine Revenue by Application (2017-2028)
6.3 North America Prophylactic Human Vaccine Market Size by Country
6.3.1 North America Prophylactic Human Vaccine Sales by Country (2017-2028)
6.3.2 North America Prophylactic Human Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Prophylactic Human Vaccine Market Size by Type
7.1.1 Europe Prophylactic Human Vaccine Sales by Type (2017-2028)
7.1.2 Europe Prophylactic Human Vaccine Revenue by Type (2017-2028)
7.2 Europe Prophylactic Human Vaccine Market Size by Application
7.2.1 Europe Prophylactic Human Vaccine Sales by Application (2017-2028)
7.2.2 Europe Prophylactic Human Vaccine Revenue by Application (2017-2028)
7.3 Europe Prophylactic Human Vaccine Market Size by Country
7.3.1 Europe Prophylactic Human Vaccine Sales by Country (2017-2028)
7.3.2 Europe Prophylactic Human Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Prophylactic Human Vaccine Market Size by Type
8.1.1 Asia Pacific Prophylactic Human Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Prophylactic Human Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Prophylactic Human Vaccine Market Size by Application
8.2.1 Asia Pacific Prophylactic Human Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Prophylactic Human Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Prophylactic Human Vaccine Market Size by Region
8.3.1 Asia Pacific Prophylactic Human Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Prophylactic Human Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Prophylactic Human Vaccine Market Size by Type
9.1.1 Latin America Prophylactic Human Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Prophylactic Human Vaccine Revenue by Type (2017-2028)
9.2 Latin America Prophylactic Human Vaccine Market Size by Application
9.2.1 Latin America Prophylactic Human Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Prophylactic Human Vaccine Revenue by Application (2017-2028)
9.3 Latin America Prophylactic Human Vaccine Market Size by Country
9.3.1 Latin America Prophylactic Human Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Prophylactic Human Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Prophylactic Human Vaccine Market Size by Type
10.1.1 Middle East and Africa Prophylactic Human Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Prophylactic Human Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Prophylactic Human Vaccine Market Size by Application
10.2.1 Middle East and Africa Prophylactic Human Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Prophylactic Human Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Prophylactic Human Vaccine Market Size by Country
10.3.1 Middle East and Africa Prophylactic Human Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Prophylactic Human Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GSK Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GSK Recent Developments
11.2 Biovac
11.2.1 Biovac Corporation Information
11.2.2 Biovac Overview
11.2.3 Biovac Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Biovac Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Biovac Recent Developments
11.3 McKesson Medical
11.3.1 McKesson Medical Corporation Information
11.3.2 McKesson Medical Overview
11.3.3 McKesson Medical Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 McKesson Medical Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 McKesson Medical Recent Developments
11.4 Merck
11.4.1 Merck Corporation Information
11.4.2 Merck Overview
11.4.3 Merck Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Merck Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Recent Developments
11.5 Merial
11.5.1 Merial Corporation Information
11.5.2 Merial Overview
11.5.3 Merial Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Merial Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merial Recent Developments
11.6 Zoetis
11.6.1 Zoetis Corporation Information
11.6.2 Zoetis Overview
11.6.3 Zoetis Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Zoetis Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Zoetis Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sanofi Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Prophylactic Human Vaccine Industry Chain Analysis
12.2 Prophylactic Human Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Prophylactic Human Vaccine Production Mode & Process
12.4 Prophylactic Human Vaccine Sales and Marketing
12.4.1 Prophylactic Human Vaccine Sales Channels
12.4.2 Prophylactic Human Vaccine Distributors
12.5 Prophylactic Human Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Prophylactic Human Vaccine Industry Trends
13.2 Prophylactic Human Vaccine Market Drivers
13.3 Prophylactic Human Vaccine Market Challenges
13.4 Prophylactic Human Vaccine Market Restraints
14 Key Findings in The Global Prophylactic Human Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Prophylactic Human Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Inactivated Vaccine
    Table 3. Major Manufacturers of Attenuated Vaccine
    Table 4. Major Manufacturers of Others
    Table 5. Global Prophylactic Human Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Prophylactic Human Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Prophylactic Human Vaccine Sales by Region (2017-2022) & (K Units)
    Table 8. Global Prophylactic Human Vaccine Sales Market Share by Region (2017-2022)
    Table 9. Global Prophylactic Human Vaccine Sales by Region (2023-2028) & (K Units)
    Table 10. Global Prophylactic Human Vaccine Sales Market Share by Region (2023-2028)
    Table 11. Global Prophylactic Human Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 12. Global Prophylactic Human Vaccine Revenue Market Share by Region (2017-2022)
    Table 13. Global Prophylactic Human Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 14. Global Prophylactic Human Vaccine Revenue Market Share by Region (2023-2028)
    Table 15. Global Prophylactic Human Vaccine Sales by Manufacturers (2017-2022) & (K Units)
    Table 16. Global Prophylactic Human Vaccine Sales Share by Manufacturers (2017-2022)
    Table 17. Global Prophylactic Human Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 18. Global Prophylactic Human Vaccine Revenue Share by Manufacturers (2017-2022)
    Table 19. Prophylactic Human Vaccine Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 20. Global Prophylactic Human Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 21. Global Prophylactic Human Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prophylactic Human Vaccine as of 2021)
    Table 22. Prophylactic Human Vaccine Manufacturing Base Distribution and Headquarters
    Table 23. Manufacturers Prophylactic Human Vaccine Product Offered
    Table 24. Date of Manufacturers Enter into Prophylactic Human Vaccine Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Prophylactic Human Vaccine Sales by Type (2017-2022) & (K Units)
    Table 27. Global Prophylactic Human Vaccine Sales by Type (2023-2028) & (K Units)
    Table 28. Global Prophylactic Human Vaccine Sales Share by Type (2017-2022)
    Table 29. Global Prophylactic Human Vaccine Sales Share by Type (2023-2028)
    Table 30. Global Prophylactic Human Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 31. Global Prophylactic Human Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 32. Global Prophylactic Human Vaccine Revenue Share by Type (2017-2022)
    Table 33. Global Prophylactic Human Vaccine Revenue Share by Type (2023-2028)
    Table 34. Prophylactic Human Vaccine Price by Type (2017-2022) & (USD/Unit)
    Table 35. Global Prophylactic Human Vaccine Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 36. Global Prophylactic Human Vaccine Sales by Application (2017-2022) & (K Units)
    Table 37. Global Prophylactic Human Vaccine Sales by Application (2023-2028) & (K Units)
    Table 38. Global Prophylactic Human Vaccine Sales Share by Application (2017-2022)
    Table 39. Global Prophylactic Human Vaccine Sales Share by Application (2023-2028)
    Table 40. Global Prophylactic Human Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 41. Global Prophylactic Human Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 42. Global Prophylactic Human Vaccine Revenue Share by Application (2017-2022)
    Table 43. Global Prophylactic Human Vaccine Revenue Share by Application (2023-2028)
    Table 44. Prophylactic Human Vaccine Price by Application (2017-2022) & (USD/Unit)
    Table 45. Global Prophylactic Human Vaccine Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 46. North America Prophylactic Human Vaccine Sales by Type (2017-2022) & (K Units)
    Table 47. North America Prophylactic Human Vaccine Sales by Type (2023-2028) & (K Units)
    Table 48. North America Prophylactic Human Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 49. North America Prophylactic Human Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 50. North America Prophylactic Human Vaccine Sales by Application (2017-2022) & (K Units)
    Table 51. North America Prophylactic Human Vaccine Sales by Application (2023-2028) & (K Units)
    Table 52. North America Prophylactic Human Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 53. North America Prophylactic Human Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 54. North America Prophylactic Human Vaccine Sales by Country (2017-2022) & (K Units)
    Table 55. North America Prophylactic Human Vaccine Sales by Country (2023-2028) & (K Units)
    Table 56. North America Prophylactic Human Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 57. North America Prophylactic Human Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 58. Europe Prophylactic Human Vaccine Sales by Type (2017-2022) & (K Units)
    Table 59. Europe Prophylactic Human Vaccine Sales by Type (2023-2028) & (K Units)
    Table 60. Europe Prophylactic Human Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 61. Europe Prophylactic Human Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 62. Europe Prophylactic Human Vaccine Sales by Application (2017-2022) & (K Units)
    Table 63. Europe Prophylactic Human Vaccine Sales by Application (2023-2028) & (K Units)
    Table 64. Europe Prophylactic Human Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 65. Europe Prophylactic Human Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 66. Europe Prophylactic Human Vaccine Sales by Country (2017-2022) & (K Units)
    Table 67. Europe Prophylactic Human Vaccine Sales by Country (2023-2028) & (K Units)
    Table 68. Europe Prophylactic Human Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 69. Europe Prophylactic Human Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 70. Asia Pacific Prophylactic Human Vaccine Sales by Type (2017-2022) & (K Units)
    Table 71. Asia Pacific Prophylactic Human Vaccine Sales by Type (2023-2028) & (K Units)
    Table 72. Asia Pacific Prophylactic Human Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 73. Asia Pacific Prophylactic Human Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 74. Asia Pacific Prophylactic Human Vaccine Sales by Application (2017-2022) & (K Units)
    Table 75. Asia Pacific Prophylactic Human Vaccine Sales by Application (2023-2028) & (K Units)
    Table 76. Asia Pacific Prophylactic Human Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 77. Asia Pacific Prophylactic Human Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 78. Asia Pacific Prophylactic Human Vaccine Sales by Region (2017-2022) & (K Units)
    Table 79. Asia Pacific Prophylactic Human Vaccine Sales by Region (2023-2028) & (K Units)
    Table 80. Asia Pacific Prophylactic Human Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 81. Asia Pacific Prophylactic Human Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 82. Latin America Prophylactic Human Vaccine Sales by Type (2017-2022) & (K Units)
    Table 83. Latin America Prophylactic Human Vaccine Sales by Type (2023-2028) & (K Units)
    Table 84. Latin America Prophylactic Human Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 85. Latin America Prophylactic Human Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 86. Latin America Prophylactic Human Vaccine Sales by Application (2017-2022) & (K Units)
    Table 87. Latin America Prophylactic Human Vaccine Sales by Application (2023-2028) & (K Units)
    Table 88. Latin America Prophylactic Human Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 89. Latin America Prophylactic Human Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 90. Latin America Prophylactic Human Vaccine Sales by Country (2017-2022) & (K Units)
    Table 91. Latin America Prophylactic Human Vaccine Sales by Country (2023-2028) & (K Units)
    Table 92. Latin America Prophylactic Human Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 93. Latin America Prophylactic Human Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 94. Middle East and Africa Prophylactic Human Vaccine Sales by Type (2017-2022) & (K Units)
    Table 95. Middle East and Africa Prophylactic Human Vaccine Sales by Type (2023-2028) & (K Units)
    Table 96. Middle East and Africa Prophylactic Human Vaccine Revenue by Type (2017-2022) & (US$ Million)
    Table 97. Middle East and Africa Prophylactic Human Vaccine Revenue by Type (2023-2028) & (US$ Million)
    Table 98. Middle East and Africa Prophylactic Human Vaccine Sales by Application (2017-2022) & (K Units)
    Table 99. Middle East and Africa Prophylactic Human Vaccine Sales by Application (2023-2028) & (K Units)
    Table 100. Middle East and Africa Prophylactic Human Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 101. Middle East and Africa Prophylactic Human Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 102. Middle East and Africa Prophylactic Human Vaccine Sales by Country (2017-2022) & (K Units)
    Table 103. Middle East and Africa Prophylactic Human Vaccine Sales by Country (2023-2028) & (K Units)
    Table 104. Middle East and Africa Prophylactic Human Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 105. Middle East and Africa Prophylactic Human Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 106. GSK Corporation Information
    Table 107. GSK Description and Major Businesses
    Table 108. GSK Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 109. GSK Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 110. GSK Recent Developments
    Table 111. Biovac Corporation Information
    Table 112. Biovac Description and Major Businesses
    Table 113. Biovac Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 114. Biovac Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 115. Biovac Recent Developments
    Table 116. McKesson Medical Corporation Information
    Table 117. McKesson Medical Description and Major Businesses
    Table 118. McKesson Medical Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 119. McKesson Medical Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 120. McKesson Medical Recent Developments
    Table 121. Merck Corporation Information
    Table 122. Merck Description and Major Businesses
    Table 123. Merck Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 124. Merck Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 125. Merck Recent Developments
    Table 126. Merial Corporation Information
    Table 127. Merial Description and Major Businesses
    Table 128. Merial Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 129. Merial Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 130. Merial Recent Developments
    Table 131. Zoetis Corporation Information
    Table 132. Zoetis Description and Major Businesses
    Table 133. Zoetis Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 134. Zoetis Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 135. Zoetis Recent Developments
    Table 136. Sanofi Corporation Information
    Table 137. Sanofi Description and Major Businesses
    Table 138. Sanofi Prophylactic Human Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 139. Sanofi Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 140. Sanofi Recent Developments
    Table 141. Key Raw Materials Lists
    Table 142. Raw Materials Key Suppliers Lists
    Table 143. Prophylactic Human Vaccine Distributors List
    Table 144. Prophylactic Human Vaccine Customers List
    Table 145. Prophylactic Human Vaccine Market Trends
    Table 146. Prophylactic Human Vaccine Market Drivers
    Table 147. Prophylactic Human Vaccine Market Challenges
    Table 148. Prophylactic Human Vaccine Market Restraints
    Table 149. Research Programs/Design for This Report
    Table 150. Key Data Information from Secondary Sources
    Table 151. Key Data Information from Primary Sources
List of Figures
    Figure 1. Prophylactic Human Vaccine Product Picture
    Figure 3. Global Prophylactic Human Vaccine Market Share by Type in 2021 & 2028
    Figure 3. Inactivated Vaccine Product Picture
    Figure 4. Attenuated Vaccine Product Picture
    Figure 5. Others Product Picture
    Figure 6. Global Prophylactic Human Vaccine Market Share by Application in 2021 & 2028
    Figure 7. Hospital
    Figure 8. Scientific Research
    Figure 9. Others
    Figure 10. Prophylactic Human Vaccine Report Years Considered
    Figure 11. Global Prophylactic Human Vaccine Sales 2017-2028 (K Units)
    Figure 12. Global Prophylactic Human Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Prophylactic Human Vaccine Revenue 2017-2028 (US$ Million)
    Figure 14. Global Prophylactic Human Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 15. Global Prophylactic Human Vaccine Sales Market Share by Region (2017-2022)
    Figure 16. Global Prophylactic Human Vaccine Sales Market Share by Region (2023-2028)
    Figure 17. North America Prophylactic Human Vaccine Sales YoY (2017-2028) & (K Units)
    Figure 18. North America Prophylactic Human Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Europe Prophylactic Human Vaccine Sales YoY (2017-2028) & (K Units)
    Figure 20. Europe Prophylactic Human Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Asia-Pacific Prophylactic Human Vaccine Sales YoY (2017-2028) & (K Units)
    Figure 22. Asia-Pacific Prophylactic Human Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Latin America Prophylactic Human Vaccine Sales YoY (2017-2028) & (K Units)
    Figure 24. Latin America Prophylactic Human Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Middle East & Africa Prophylactic Human Vaccine Sales YoY (2017-2028) & (K Units)
    Figure 26. Middle East & Africa Prophylactic Human Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. The Prophylactic Human Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 28. The Top 5 and 10 Largest Manufacturers of Prophylactic Human Vaccine in the World: Market Share by Prophylactic Human Vaccine Revenue in 2021
    Figure 29. Global Prophylactic Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 30. Global Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
    Figure 31. Global Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
    Figure 32. Global Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
    Figure 33. Global Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
    Figure 34. North America Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
    Figure 35. North America Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
    Figure 36. North America Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
    Figure 37. North America Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
    Figure 38. North America Prophylactic Human Vaccine Sales Share by Country (2017-2028)
    Figure 39. North America Prophylactic Human Vaccine Revenue Share by Country (2017-2028)
    Figure 40. U.S. Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 41. Canada Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 42. Europe Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
    Figure 43. Europe Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
    Figure 44. Europe Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
    Figure 45. Europe Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
    Figure 46. Europe Prophylactic Human Vaccine Sales Share by Country (2017-2028)
    Figure 47. Europe Prophylactic Human Vaccine Revenue Share by Country (2017-2028)
    Figure 48. Germany Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 49. France Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 50. U.K. Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 51. Italy Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 52. Russia Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 53. Asia Pacific Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Prophylactic Human Vaccine Sales Share by Region (2017-2028)
    Figure 58. Asia Pacific Prophylactic Human Vaccine Revenue Share by Region (2017-2028)
    Figure 59. China Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 60. Japan Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 61. South Korea Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 62. India Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 63. Australia Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 64. Taiwan Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 65. Indonesia Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 66. Thailand Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 67. Malaysia Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 68. Philippines Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 69. Latin America Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
    Figure 70. Latin America Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
    Figure 71. Latin America Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
    Figure 72. Latin America Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
    Figure 73. Latin America Prophylactic Human Vaccine Sales Share by Country (2017-2028)
    Figure 74. Latin America Prophylactic Human Vaccine Revenue Share by Country (2017-2028)
    Figure 75. Mexico Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 76. Brazil Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 77. Argentina Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 78. Middle East and Africa Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Prophylactic Human Vaccine Sales Share by Country (2017-2028)
    Figure 83. Middle East and Africa Prophylactic Human Vaccine Revenue Share by Country (2017-2028)
    Figure 84. Turkey Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 85. Saudi Arabia Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 86. U.A.E Prophylactic Human Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 87. Prophylactic Human Vaccine Value Chain
    Figure 88. Prophylactic Human Vaccine Production Process
    Figure 89. Channels of Distribution
    Figure 90. Distributors Profiles
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$4900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$7350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$9800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global Vaccine Temperature Monitoring System Market Insights Forecast to 2028
Global Vaccine Temperature Monitoring System Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-10F7540
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Nelfinavir Market Insights Forecast to 2028
Global Nelfinavir Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-25I7469
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Vancomycin Market Insights and Forecast to 2028
Global Vancomycin Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-20N7760
Tue May 03 00:00:00 UTC 2022

Add to Cart

Global Hepatitis B Human Immunoglobulin Market Insights and Forecast to 2028
Global Hepatitis B Human Immunoglobulin Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-22V7718
Tue May 03 00:00:00 UTC 2022

Add to Cart